The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Per-SVR (pronounced “Persevere!”) Study is Recruiting Participants

Have HEP C or recently treated with DAAs? Be part of RESEARCH! WHAT is Per-SVR? Here is a great opportunity! The Per-SVR (pronounced “Persevere!”) Study is recruiting participants in a multi-year study to learn more about the experiences of people who have been treated with the new “DAA” hep C treatments.  The information gathered will lead to better policies and services for those living with or at risk of contracting hep C. WHAT would I have to do? P